{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:05:36Z","timestamp":1791993936834,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13023-016-0441-z","type":"journal-article","created":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T01:52:03Z","timestamp":1462326723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant"],"prefix":"10.1186","volume":"11","author":[{"given":"Malte","family":"Lenders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Kurschat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Canaan-K\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Duning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Stypmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Reiermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Blaschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan-Martin","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,4]]},"reference":[{"key":"441_CR1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ. Fabry\u2019s disease. Lancet. 2008;372:1427\u201335.","journal-title":"Lancet"},{"key":"441_CR2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34:236\u201342.","journal-title":"Eur J Clin Invest"},{"key":"441_CR3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","volume":"7","author":"M Niemann","year":"2014","unstructured":"Niemann M, Rolfs A, St\u00f6rk S, Bijnens B, Breunig F, Beer M, Ertl G, Wanner C, Weidemann F. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet. 2014;7:8\u201316.","journal-title":"Circ Cardiovasc Genet"},{"key":"441_CR4","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1007\/s10545-008-0972-0","volume":"31","author":"JP Oliveira","year":"2008","unstructured":"Oliveira JP, Ferreira S, Reguenga C, Carvalho F, M\u00e5nsson JE. The g.1170C\u2009>\u2009T polymorphism of the 5\u2019 untranslated region of the human alpha-galactosidase gene is associated with decreased enzyme expression--evidence from a family study. J Inherit Metab Dis. 2008;31:S405\u201313.","journal-title":"J Inherit Metab Dis"},{"key":"441_CR5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","volume":"1802","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, Vd Bergh Weerman MA, Groener JE, Poorthuis BJ, Hollak CE, Aerts JM. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta. 2010;1802:741\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"441_CR6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ymgme.2012.07.003","volume":"107","author":"S Mitobe","year":"2012","unstructured":"Mitobe S, Togawa T, Tsukimura T, Kodama T, Tanaka T, Doi K, Noiri E, Akai Y, Saito Y, Yoshino M, Takenaka T, Saito S, Ohno K, Sakuraba H. Mutant \u03b1-galactosidase A with M296I does not cause elevation of the plasma globotriaosylsphingosine level. Mol Genet Metab. 2012;107:623\u20136.","journal-title":"Mol Genet Metab"},{"key":"441_CR7","doi-asserted-by":"crossref","first-page":"e55565","DOI":"10.1371\/journal.pone.0055565","volume":"8","author":"M Lenders","year":"2013","unstructured":"Lenders M, Duning T, Schelleckes M, Schmitz B, Stander S, Rolfs A, Brand SM, Brand E. Multifocal white matter lesions associated with the D313Y mutation of the \u03b1-galactosidase A gene. PLoS One. 2013;8:e55565.","journal-title":"PLoS One"},{"key":"441_CR8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/STROKEAHA.112.663708","volume":"44","author":"A Rolfs","year":"2013","unstructured":"Rolfs A, Fazekas F, Grittner U, Dichgans M, Martus P, Holzhausen M, B\u00f6ttcher T, Heuschmann PU, Tatlisumak T, Tanislav C, Jungehulsing GJ, Giese AK, Putaala J, Huber R, Bodechtel U, Lichy C, Enzinger C, Schmidt R, Hennerici MG, Kaps M, Kessler C, Lackner K, Paschke E, Meyer W, Mascher H, Riess O, Kolodny E, Norrving B, Stroke in Young Fabry Patients (sifap) Investigators. Acute cerebrovascular disease in the young: The stroke in Fabry patients study. Stroke. 2013;44:340\u20139.","journal-title":"Stroke"},{"key":"441_CR9","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.clineuro.2012.11.003","volume":"115","author":"I Brabander De","year":"2013","unstructured":"De Brabander I, Yperzeele L, Groote CC, Brouns R, Baker R, Belachew S, Delbecq J, De Keulenaer G, Dethy S, Eyskens F, Fumal A, Hemelsoet D, Hughes D, Jeangette S, Nuytten D, Redondo P, Sadzot B, Sindic C, Sheorajpanday R, Thijs V, Van Broeckhoven C, De Deyn PP. Phenotypical characterization of \u03b1-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young. Clin Neurol Neurosurg. 2013;115:1088\u201393.","journal-title":"Clin Neurol Neurosurg"},{"key":"441_CR10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cge.12449","volume":"88","author":"BE Smid","year":"2015","unstructured":"Smid BE, Hollak CE, Poorthuis BJ, van den Bergh Weerman MA, Florquin S, Kok WE, Lekanne Deprez RH, Timmermans J, Linthorst GE. Diagnostic dilemmas in Fabry disease: a case series study on GLA mutations of unknown clinical significance. Clin Genet. 2015;88:161\u20136.","journal-title":"Clin Genet"},{"key":"441_CR11","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13023-014-0178-5","volume":"9","author":"M Schelleckes","year":"2014","unstructured":"Schelleckes M, Lenders M, Guske K, Schmitz B, Tanislav C, St\u00e4nder S, Metze D, Katona I, Weis J, Brand SM, Duning T, Brand E. Cryptogenic stroke and small fiber neuropathy of unknown etiology in patients with alpha-galactosidase A -10\u00a0T genotype. Orphanet J Rare Dis. 2014;9:178.","journal-title":"Orphanet J Rare Dis"},{"key":"441_CR12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13023-014-0111-y","volume":"9","author":"HC Liu","year":"2014","unstructured":"Liu HC, Lin HY, Yang CF, Liao HC, Hsu TR, Lo CW, Chang FP, Huang CK, Lu YH, Lin SP, Yu WC, Niu DM. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4\u2009+\u2009919G\u2009>\u2009A). Orphanet J Rare Dis. 2014;9:111.","journal-title":"Orphanet J Rare Dis"},{"key":"441_CR13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/8904_2012_167","volume":"8","author":"W Terryn","year":"2013","unstructured":"Terryn W, Vanholder R, Hemelsoet D, Leroy BP, Van Biesen W, De Schoenmakere G, Wuyts B, Claes K, De Backer J, De Paepe G, Fogo A, Praet M, Poppe B. Questioning the Pathogenic Role of the GLA p.Ala143Thr \u201cMutation\u201d in Fabry Disease: Implications for Screening Studies and ERT. JIMD Rep. 2013;8:101\u20138.","journal-title":"JIMD Rep"},{"key":"441_CR14","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1681\/ASN.2013060585","volume":"25","author":"F Weidemann","year":"2014","unstructured":"Weidemann F, Kr\u00e4mer J, Duning T, Lenders M, Canaan-K\u00fchl S, Krebs A, Guerrero Gonz\u00e1lez H, Sommer C, \u00dc\u00e7eyler N, Niemann M, St\u00f6rk S, Schelleckes M, Reiermann S, Stypmann J, Brand SM, Wanner C, Brand E. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol. 2014;25:837\u201349.","journal-title":"J Am Soc Nephrol"},{"key":"441_CR15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"441_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1\u2013150.","journal-title":"Kidney Int Suppl"},{"key":"441_CR17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1159\/000210432","volume":"27","author":"P Amarenco","year":"2009","unstructured":"Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebrovasc Dis. 2009;27:493\u2013501.","journal-title":"Cerebrovasc Dis"},{"key":"441_CR18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","volume":"65","author":"C Whybra","year":"2004","unstructured":"Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, Gal A, Beck M. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65:299\u2013307.","journal-title":"Clin Genet"},{"key":"441_CR19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymgme.2009.10.178","volume":"99","author":"EH Giannini","year":"2010","unstructured":"Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, West M, Germain DP, Wanner C, Waldek S, Clarke JT, Mengel E, Strotmann JM, Warnock DG, Linhart A. A validated disease severity scoring system for Fabry disease. Mol Genet Metab. 2010;99:283\u201390.","journal-title":"Mol Genet Metab"},{"key":"441_CR20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000322153","volume":"31","author":"A Rolfs","year":"2011","unstructured":"Rolfs A, Martus B, Heuschmann PU, Grittner U, Holzhausen M, Tatlisumak T, B\u00f6ttcher T, Fazekas F, Enzinger C, Ropele S, Schmidt R, Riess O, Norrving B, sifap1 Investigators. Protocol and methodology of the stroke in young Fabry patients (sifap1) study: A prospective multicenter European study of 5,024 young stroke patients aged 18\u201355 years. Cerebrovasc Dis. 2011;31:253\u201362.","journal-title":"Cerebrovasc Dis"},{"key":"441_CR21","first-page":"157","volume":"81","author":"RJ Desnick","year":"1973","unstructured":"Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W. Fabry\u2019s disease: enzymatic diagnosis of hemizygotes and heterozygotes. J Lab Clin Med. 1973;81:157\u201371.","journal-title":"J Lab Clin Med"},{"key":"441_CR22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0009-8981(81)90384-3","volume":"112","author":"JS Mayes","year":"1981","unstructured":"Mayes JS, Scheerer JB, Sifers RN, Donaldson ML. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry\u2019s disease. Clin Chim Acta. 1981;112:247\u201351.","journal-title":"Clin Chim Acta"},{"key":"441_CR23","first-page":"1229","volume":"51","author":"RC Allen","year":"1992","unstructured":"Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992;51:1229\u201339.","journal-title":"Am J Hum Genet"},{"key":"441_CR24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2007.05.082","volume":"359","author":"S Shin","year":"2007","unstructured":"Shin S, Murray GJ, Kluepfer-Stahl S, Cooney AM, Quirk JA, Schiffmann R, Brady RO, Kaneski CR. Screening for pharmacological chaperones in Fabry disease. Biochem Biophys Res Commun. 2007;359:168\u201373.","journal-title":"Biochem Biophys Res Commun"},{"key":"441_CR25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0002-8703(77)80064-1","volume":"93","author":"J Mehta","year":"1977","unstructured":"Mehta J, Tuna N, Moller JH, Desnick RJ. Electrocardiographic and vectorcardiographic abnormalities in Fabry\u2019s disease. Am Heart J. 1977;93:699\u2013705.","journal-title":"Am Heart J"},{"key":"441_CR26","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.amjcard.2010.07.016","volume":"106","author":"FI Gambarin","year":"2010","unstructured":"Gambarin FI, Disabella E, Narula J, Diegoli M, Grasso M, Serio A, Favalli BM, Agozzino M, Tavazzi L, Fraser AG, Arbustini E. When should cardiologists suspect Anderson-Fabry disease? Am J Cardiol. 2010;106:1492\u20139.","journal-title":"Am J Cardiol"},{"key":"441_CR27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/STROKEAHA.110.579409","volume":"41","author":"R Brouns","year":"2010","unstructured":"Brouns R, Thijs V, Eyskens F, Van den Broeck M, Belachew S, Van Broeckhoven C, Redondo P, Hemelsoet D, Fumal A, Jeangette S, Verslegers W, Baker R, Hughes D, De Deyn PP, BeFaS Investigators. Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke. 2010;41:863\u20138.","journal-title":"Stroke"},{"key":"441_CR28","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jpeds.2004.01.051","volume":"144","author":"RJ Desnick","year":"2004","unstructured":"Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr. 2004;144:S20\u20136.","journal-title":"J Pediatr"},{"key":"441_CR29","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.10.005","volume":"22","author":"V Dubuc","year":"2013","unstructured":"Dubuc V, Moore DF, Gioia LC, Saposnik G, Selchen D, Lanthier S. Prevalence of Fabry disease in young patients with cryptogenic ischemic stroke. J Stroke Cerebrovasc Dis. 2013;22:1288\u201392.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"441_CR30","author":"MJ Ferraz","year":"2016","unstructured":"Ferraz MJ, Marques AR, Appelman MD, Verhoek M, Strijland A, Mirzaian M, Scheij S, Ouairy CM, Lahav D, Wisse P, Overkleeft HS, Boot RG, Aerts JM. Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases. FEBS Lett. 2016. doi: 10.1002\/1873-3468.12104 [Epub ahead of print].","journal-title":"FEBS Lett"},{"key":"441_CR31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain D. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89:44\u20135.","journal-title":"Clin Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0441-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T12:38:34Z","timestamp":1498307914000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-016-0441-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,4]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["441"],"URL":"https:\/\/doi.org\/10.1186\/s13023-016-0441-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,4]]},"article-number":"54"}}